Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.

Cancer research communications - 1 May 2025

Garcia Nina Marie G, Becerra Jessica N, Srinivasan Sharan, McKinney Brock J, DiMarco Ashley V, Wu Feinan, Fitzgibbon Matthew, Alvarez James V

Abstract excerpt

APOBEC mutagenesis is one of the most common endogenous sources of mutations in human cancer and is a major source of genetic intratumor heterogeneity. High levels of APOBEC mutagenesis are associated with poor prognosis and aggressive disease across diverse cancers, but the mechanistic and functional impacts of APOBEC mutagenesis on tumor evolution and therapy resistance remain relatively unexplored. To address...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to APOBEC Deaminases
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to Cytidine Deaminase

Share to Drug Resistance, Neoplasm

Share to Gefitinib

Share to Minor Histocompatibility Antigens

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 40323013
DOI: 10.1158/2767-9764.CRC-24-0442
PMCID: PMC12093302

Genes

EGFR
APOBEC3B

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

APOBEC3 Activity Promotes the Survival and Evolution of Drug-Tolerant Persister Cells during EGFR Inhibitor Resistance in Lung Cancer.PMID 40323013Read ↗

APOBEC3 activity promotes the survival and evolution of drug-tolerant persister cells during acquired resistance to EGFR inhibitors in lung cancerSemantic proximity Read ↗

Therapy-induced APOBEC3A drives evolution of persistent cancer cells.Semantic proximity Read ↗

Targeted cancer therapy induces APOBEC fuelling the evolution of drug resistanceSemantic proximity Read ↗

APOBEC3A drives acquired resistance to targeted therapies in non-small cell lung cancerSemantic proximity Read ↗

The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.Semantic proximity Read ↗

APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Semantic proximity Read ↗

Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.Semantic proximity Read ↗

Mechanisms of Acquired Resistance and Tolerance to EGFR Targeted Therapy in Non-Small Cell Lung CancerSemantic proximity Read ↗

Neuroendocrine-like/EMT dedifferentiation mediates resistance to EGFR inhibitors via the NRG1/HER3 axisSemantic proximity Read ↗

Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous MutatorsSemantic proximity Read ↗

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC.Semantic proximity Read ↗

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.